HighPoint Advisor Group’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $310K | Sell |
1,573
-15,348
| -91% | -$2.96M | 0.01% | 525 |
|
|
2025
Q4 | $3.11M | Buy |
16,921
+2,406
| +17% | +$422K | 0.07% | 244 |
|
|
2025
Q3 | $2.23M | Buy |
14,515
+1,101
| +8% | +$167K | 0.11% | 149 |
|
|
2025
Q2 | $1.87M | Buy |
13,414
+1,358
| +11% | +$190K | 0.1% | 164 |
|
|
2025
Q1 | $1.73M | Buy |
12,056
+966
| +9% | +$140K | 0.1% | 160 |
|
|
2024
Q4 | $1.61M | Sell |
11,090
-94
| -0.8% | -$13.2K | 0.09% | 181 |
|
|
2024
Q3 | $1.6M | Sell |
11,184
-672
| -6% | -$108K | 0.09% | 170 |
|
|
2024
Q2 | $1.85M | Sell |
11,856
-2,081
| -15% | -$313K | 0.11% | 148 |
|
|
2024
Q1 | $2.16M | Buy |
13,937
+3,669
| +36% | +$486K | 0.15% | 117 |
|
|
2023
Q4 | $1.35M | Buy |
+10,268
| New | +$1.33M | 0.1% | 173 |
|
|
2022
Q2 | $967K | Buy |
+7,273
| New | +$954K | 0.11% | 157 |
|
|
2021
Q3 | $1.05M | Buy |
8,775
+246
| +3% | +$28.6K | 0.1% | 156 |
|
|
2021
Q2 | $1.02M | Buy |
8,529
+1,345
| +19% | +$148K | 0.1% | 163 |
|
|
2021
Q1 | $718K | Buy |
7,184
+132
| +2% | +$13.3K | 0.08% | 195 |
|
|
2020
Q4 | $711K | Buy |
7,052
+2,012
| +40% | +$213K | 0.09% | 190 |
|
|
2020
Q3 | $556K | Buy |
5,040
+2,585
| +105% | +$288K | 0.1% | 171 |
|
|
2020
Q2 | $262K | Sell |
2,455
-15
| -0.6% | -$1.55K | 0.06% | 264 |
|
|
2020
Q1 | $252K | Sell |
2,470
-88
| -3% | -$8.28K | 0.06% | 246 |
|
|
2019
Q4 | $259K | Sell |
2,558
-226
| -8% | -$21.3K | 0.05% | 287 |
|
|
2019
Q3 | $263K | Buy |
2,784
+48
| +2% | +$4.16K | 0.06% | 268 |
|
|
2019
Q2 | $220K | Buy |
2,736
+26
| +1% | +$2.04K | 0.05% | 295 |
|
|
2019
Q1 | $205K | Sell |
2,710
-100
| -4% | -$7.88K | 0.05% | 307 |
|
|
2018
Q4 | $227K | Sell |
2,810
-800
| -22% | -$62.5K | 0.06% | 274 |
|
|
2018
Q3 | $285K | Sell |
3,610
-377
| -9% | -$28.5K | 0.08% | 236 |
|
|
2018
Q2 | $303K | Sell |
3,987
-646
| -14% | -$46.5K | 0.08% | 228 |
|
|
2018
Q1 | $337K | Sell |
4,633
-642
| -12% | -$44.5K | 0.09% | 216 |
|
|
2017
Q4 | $359K | Buy |
5,275
+114
| +2% | +$7.69K | 0.1% | 198 |
|
|
2017
Q3 | $352K | Buy |
5,161
+478
| +10% | +$30.2K | 0.11% | 194 |
|
|
2017
Q2 | $283K | Hold |
4,683
| – | – | 0.09% | 215 |
|
|
2017
Q1 | $283K | Buy |
4,683
+523
| +13% | +$30.4K | 0.09% | 215 |
|
|
2016
Q4 | $244K | Sell |
4,160
-1,329
| -24% | -$75.5K | 0.08% | 242 |
|
|
2016
Q3 | $300K | Buy |
5,489
+758
| +16% | +$49.5K | 0.11% | 213 |
|
|
2016
Q2 | $323K | Buy |
4,731
+1,798
| +61% | +$104K | 0.11% | 191 |
|
|
2016
Q1 | $177K | Sell |
2,933
-390
| -12% | -$23.4K | 0.11% | 191 |
|
|
2015
Q4 | $209K | Buy |
+3,323
| New | +$218K | 0.14% | 173 |
|
Other funds holding AZN
IA
VCM
VAM
HighPoint Advisor Group's AZN Position: Q1 2026 in Review
HighPoint Advisor Group reduced its AstraZeneca (AZN) stake by 91% in Q1 2026, selling an estimated $2.96M and leaving 1,573 shares worth $310K. The position accounts for 0.01% of the portfolio, ranked #525.
HighPoint Advisor Group first reported a position in AZN in Q4 2015 and has held it in 35 quarters since. The position peaked at $3.11M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- HighPoint Advisor Group held 1,573 shares of AstraZeneca worth $310K as of Q1 2026.
- HighPoint Advisor Group sold 15,348 AstraZeneca shares in Q1 2026, an estimated $2.96M.
- AstraZeneca made up 0.01% of HighPoint Advisor Group's portfolio in Q1 2026, its #525 holding.
- HighPoint Advisor Group first reported a position in AstraZeneca in Q4 2015 and has held it in 35 quarters since.
- HighPoint Advisor Group's AstraZeneca position peaked at $3.11M in Q4 2025.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.